Pinnacle Medicines, a pioneer in oral peptide therapeutics, announced an additional $89 million in Series B funding to advance its pipeline into clinical trials.
The financing was co-led by LAV and Foresite Capital with participation from existing investors including Quan Capital, Hankang Capital, RA Capital Management, Logos Capital and OrbiMed. The company has raised $134 million to date after incubation by OrbiMed and other healthcare specialist investors. Achievements will support the advancement of the oral peptide pipeline through clinical … Read more
